Open AccessComplete, refractory dysphagia in a dermatomyositis patient with positive anti-NXP-2 antibodies
Author(s) -
Claudia Cobilinschi,
Cristian Cobilinschi,
Alexandra Constantinescu,
Ruxandra Ionescu,
Daniela Opriş-Belinski
Publication year - 2021
Publication title -
romanian journal of rheumatology
Language(s) - English
Resource type - Journals
eISSN - 2069-6086
pISSN - 1843-0791
DOI - 10.37897/rjr.2021.4.7
Subject(s) - dysphagia , medicine , dermatomyositis , rash , malignancy , weakness , muscle weakness , refractory (planetary science) , autoantibody , gastroenterology , peripheral edema , dermatology , cyclophosphamide , immunology , antibody , adverse effect , surgery , chemotherapy , physics , astrobiology
Dermatomyositis (DM) is a rare autoimmune disorder defined by weakness of the striated muscles and a distinctive skin rash. Dysphagia is a serious symptom that can be difficult to manage, severely impacting quality of life and long-term survival. The aim of this report is to highlight a case of an anti-NXP-2 positive DM with severe dysphagia refractory to multiple therapies, including steroids, cyclophosphamide and intravenous immunoglobulins. Anti-NXP-2 autoantibodies indicate a specific disease phenotype adding severe muscle weakness, dysphagia, peripheral edema and underlying malignancy.